CN116286519B - Lactobacillus paracasei KS3 and application thereof in preparation of anti-aging and digestion-aiding foods and medicines - Google Patents
Lactobacillus paracasei KS3 and application thereof in preparation of anti-aging and digestion-aiding foods and medicines Download PDFInfo
- Publication number
- CN116286519B CN116286519B CN202310235096.9A CN202310235096A CN116286519B CN 116286519 B CN116286519 B CN 116286519B CN 202310235096 A CN202310235096 A CN 202310235096A CN 116286519 B CN116286519 B CN 116286519B
- Authority
- CN
- China
- Prior art keywords
- lactobacillus paracasei
- strain
- paracasei
- probiotic
- resisting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000186605 Lactobacillus paracasei Species 0.000 title claims abstract description 118
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 235000013305 food Nutrition 0.000 title abstract description 16
- 230000003712 anti-aging effect Effects 0.000 title abstract description 7
- 229940079593 drug Drugs 0.000 title abstract description 6
- 239000003814 drug Substances 0.000 title abstract description 6
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims abstract description 46
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 42
- 239000006041 probiotic Substances 0.000 claims abstract description 37
- 235000018291 probiotics Nutrition 0.000 claims abstract description 37
- 230000000529 probiotic effect Effects 0.000 claims abstract description 33
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 27
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 27
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 27
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 21
- 108091005804 Peptidases Proteins 0.000 claims abstract description 10
- 239000004365 Protease Substances 0.000 claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 230000001580 bacterial effect Effects 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000000544 cholinesterase inhibitor Substances 0.000 claims description 6
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims description 5
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims description 5
- 230000000813 microbial effect Effects 0.000 claims description 5
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 108010084185 Cellulases Proteins 0.000 claims description 2
- 102000005575 Cellulases Human genes 0.000 claims description 2
- 102000035195 Peptidases Human genes 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 37
- 102100024295 Maltase-glucoamylase Human genes 0.000 abstract description 16
- 108010028144 alpha-Glucosidases Proteins 0.000 abstract description 16
- 238000010521 absorption reaction Methods 0.000 abstract description 14
- 102000012440 Acetylcholinesterase Human genes 0.000 abstract description 13
- 108010022752 Acetylcholinesterase Proteins 0.000 abstract description 13
- 229940022698 acetylcholinesterase Drugs 0.000 abstract description 13
- 230000001737 promoting effect Effects 0.000 abstract description 13
- 239000001913 cellulose Substances 0.000 abstract description 11
- 229920002678 cellulose Polymers 0.000 abstract description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 10
- 239000008103 glucose Substances 0.000 abstract description 10
- 230000002401 inhibitory effect Effects 0.000 abstract description 10
- 230000000968 intestinal effect Effects 0.000 abstract description 10
- 108010059892 Cellulase Proteins 0.000 abstract description 9
- 230000006870 function Effects 0.000 abstract description 9
- 241000193830 Bacillus <bacterium> Species 0.000 abstract description 8
- 206010010774 Constipation Diseases 0.000 abstract description 8
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract description 8
- 229940106157 cellulase Drugs 0.000 abstract description 8
- 230000029087 digestion Effects 0.000 abstract description 8
- 102000004169 proteins and genes Human genes 0.000 abstract description 8
- 108090000623 proteins and genes Proteins 0.000 abstract description 8
- 206010061218 Inflammation Diseases 0.000 abstract description 7
- 235000013351 cheese Nutrition 0.000 abstract description 7
- 230000009286 beneficial effect Effects 0.000 abstract description 6
- 210000004369 blood Anatomy 0.000 abstract description 6
- 239000008280 blood Substances 0.000 abstract description 6
- 230000004054 inflammatory process Effects 0.000 abstract description 5
- 230000008855 peristalsis Effects 0.000 abstract description 5
- 206010016946 Food allergy Diseases 0.000 abstract description 4
- 230000032683 aging Effects 0.000 abstract description 4
- 235000021110 pickles Nutrition 0.000 abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 2
- 230000031891 intestinal absorption Effects 0.000 abstract description 2
- 230000037303 wrinkles Effects 0.000 abstract description 2
- 239000002609 medium Substances 0.000 description 20
- 238000000855 fermentation Methods 0.000 description 19
- 230000004151 fermentation Effects 0.000 description 19
- 239000006228 supernatant Substances 0.000 description 15
- 230000005526 G1 to G0 transition Effects 0.000 description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 13
- 241000186660 Lactobacillus Species 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 238000011160 research Methods 0.000 description 11
- 210000001035 gastrointestinal tract Anatomy 0.000 description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 241000282326 Felis catus Species 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 229940099596 manganese sulfate Drugs 0.000 description 5
- 239000011702 manganese sulphate Substances 0.000 description 5
- 235000007079 manganese sulphate Nutrition 0.000 description 5
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 108020004465 16S ribosomal RNA Proteins 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000001888 Peptone Substances 0.000 description 4
- 108010080698 Peptones Proteins 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 230000001153 anti-wrinkle effect Effects 0.000 description 4
- 235000015278 beef Nutrition 0.000 description 4
- 229940041514 candida albicans extract Drugs 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 235000021109 kimchi Nutrition 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000015654 memory Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 235000019319 peptone Nutrition 0.000 description 4
- 235000021574 pickled cabbage Nutrition 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000001632 sodium acetate Substances 0.000 description 4
- 235000017281 sodium acetate Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 4
- 235000011046 triammonium citrate Nutrition 0.000 description 4
- 239000001393 triammonium citrate Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000000593 degrading effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000004262 Food Hypersensitivity Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000003527 anti-angiogenesis Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000007177 brain activity Effects 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000003930 cognitive ability Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000020932 food allergy Nutrition 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 239000006872 mrs medium Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 208000019399 Colonic disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 201000009840 acute diarrhea Diseases 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 238000013272 agar well diffusion method Methods 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000002361 compost Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000004149 ethanol metabolism Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003446 memory effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000002068 microbial inoculum Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000006873 mp medium Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920003168 pharmaceutical polymer Polymers 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 238000005381 potential energy Methods 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000006965 reversible inhibition Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
- C12N9/2437—Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/005—Amino acids other than alpha- or beta amino acids, e.g. gamma amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/42—Hydroxy-carboxylic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention belongs to the technical field of probiotics and application thereof, and particularly relates to a cheese bacillus strain KS3 and application thereof in preparation of anti-aging and digestion-aiding foods and medicines. In order to further develop and utilize the probiotic functions of the lactobacillus paracasei, the invention separates a lactobacillus paracasei (Lacticaseibacillus paracasei) KS3 strain from pickle samples, and the strain has the probiotic effects of producing protease, cellulase, 3-hydroxybutyric acid, gamma-aminobutyric acid and hyaluronic acid, inhibiting alpha-glucosidase activity, acetylcholinesterase activity and the like. Therefore, the strain has the beneficial effects of promoting digestion and absorption of protein food to improve protein allergy, promoting absorption of cellulose to improve constipation, resisting inflammation and improving intestinal flora, resisting depression and dispelling alcohol, resisting aging and resisting wrinkle, reducing blood glucose, promoting intestinal absorption and peristalsis and the like, and has important application value and economic value.
Description
Technical Field
The invention belongs to the technical field of probiotics and application thereof, and particularly relates to a cheese bacillus strain KS3 and application thereof in preparation of anti-aging and digestion-aiding foods and medicines.
Background
Lactobacillus paracasei (Lactobacilli paracasei), also known as Lactobacillus paracasei, is a facultative anaerobic, motionless, spore-free gram-positive short or long rod-shaped polymorphous bacillus. The bacteria have different lengths, the general width is smaller than 1.5 mu m, the two ends are level and square, the arrangement mode is mostly short chain or long chain, and spherical bacteria can be seen in some cases.
The lactobacillus paracasei is one of strains for food production and processing, and is safe and nontoxic to eat. Meanwhile, the lactobacillus paracasei is also a probiotic beneficial to human health, and can promote intestinal peristalsis, and keep intestinal flora in balance, so that the resistance of the human body is enhanced; has effects of promoting specific and nonspecific immunity, enhancing immunity, and preventing diseases; is beneficial to development, enhances the physique of human body, delays the aging of the organism, prolongs the life of the human body, can colonise the intestinal tract, effectively regulates the flora in the intestinal tract, maintains the internal environment of the intestinal tract, and prevents constipation caused by dysbacteriosis. At present, lactobacillus paracasei has become a hotspot for research as a probiotic lactobacillus with great potential and is being continuously used to make probiotic preparations suitable for humans and animals.
At present, different strains of lactobacillus paracasei have been reported to have different probiotic functions: (1) antibacterial action: the Lactobacillus paracasei not only has antagonism to a plurality of bacteria, but also can inhibit the growth of yeast and mould. Studies have shown that Lactobacillus paracasei can significantly reduce the number of Clostridium and Enterobacter in weaned piglets. (2) has good physiological effects: the lactobacillus paracasei serving as probiotics can regulate the flora balance of human intestinal tracts, enhance the immune function, and has wide development prospect in the aspects of disease prevention and the like. Studies show that the lactobacillus paracasei can enhance the nonspecific resistance of a host to microbial pathogens, accelerate the removal effect of pathogens in intestinal tracts, treat intestinal flora disturbance, inhibit intestinal permeability enhancement, and prevent food allergy and acute diarrhea; also can increase anti-low density oxidized lipid antibody and CD 4T-lymphocyte, enhance granulocyte phagocytosis, and further perform immunoregulation on host, and prevent tumor. (3) The strains of the cheese bacillus paracasei LC-01, K56, LC19 and the like have good effects of improving constipation and relaxing bowels. (4) promote intestinal peristalsis: the lactobacillus paracasei can play a role of probiotics, not only is helpful for digestion of food in intestinal tracts, but also can relieve diarrhea and diarrhea symptoms. (5) lowering blood pressure: the Lactobacillus paracasei can lower cholesterol and blood pressure. (6) prevention of tumors: the Lactobacillus paracasei can prevent tumor growth, and has no influence on health, and good safety.
The diversity of the sources of the cheese bacillus paracasei results in genetic and functional diversity. However, there are still few studies on the isolation and identification of lactobacillus paracasei, the probiotic properties and the metabolic mechanism, which also affect the development and utilization of lactobacillus paracasei to some extent. Therefore, it is necessary to make the Lactobacillus paracasei function better according to its different sources, such as determining its efficacy according to the function of the strain or the probiotic metabolite, and defining its application prospect. In conclusion, the research and application of the probiotic Lactobacillus paracasei have a relatively wide development space.
Disclosure of Invention
In order to overcome the defects in the prior art, the invention separates a strain KS3 of Lactobacillus paracasei from pickle samples, and the strain KS3 of Lactobacillus paracasei has various probiotics effects including cellulase production, 3-hydroxybutyric acid production, hyaluronic acid production, alpha-glucosidase inhibition, acetylcholinesterase inhibition and the like, and has great potential application value.
In order to achieve the above purpose, the present invention is realized by the following technical scheme:
in a first aspect, the present invention provides a strain of lactobacillus paracasei (lactobacillus paracasei) KS3, said strain of lactobacillus paracasei KS3 being deposited with the chinese collection of typical cultures at month 27 of 2022 under the accession number: cctccc No. M20221510; the 16S rDNA complete sequence of the Lactobacillus paracasei KS3 strain is shown in SEQ ID No: 1.
In a second aspect, the invention provides the use of a strain of Lactobacillus paracasei (Lactobacilli sp. Asaei) KS3 according to the first aspect for producing cellulases.
The research shows that the probiotic Lactobacillus paracasei KS3 strain can produce cellulase, which suggests that the Lactobacillus paracasei KS3 is expected to be used in the fields of promoting digestion and absorption of dietary components, improving constipation, reducing cholesterol, assisting in treating diabetes and the like.
In a third aspect the invention provides the use of a strain of Lactobacillus paracasei (Lactobacilli sp. Asasei) KS3 according to the first aspect for the production of 3-hydroxybutyric acid.
The research shows that the probiotic Lactobacillus paracasei KS3 strain can produce 3-hydroxybutyric acid (3-HB), which suggests that the Lactobacillus paracasei KS3 is expected to be used in the fields of providing energy for various activities of the body, resisting osteoporosis, preventing and treating chronic syndrome and the like.
In a fourth aspect, the invention provides the use of a strain of Lactobacillus paracasei (Lactobacilli sp. Asaei) KS3 according to the first aspect for the production of hyaluronic acid.
The research shows that the probiotics lactobacillus paracasei KS3 strain can produce Hyaluronic Acid (HA), which suggests that the lactobacillus paracasei KS3 is expected to be used in the fields of anti-inflammation, anti-angiogenesis, anti-aging, wound inflammation promotion, healing and the like.
In a fifth aspect, the invention provides the use of a strain of Lactobacillus paracasei (Lactobacilli sp. Asaei) KS3 according to the first aspect for the preparation of an alpha-glucosidase inhibitor.
The research shows that the probiotic Lactobacillus paracasei KS3 strain can effectively inhibit the activity of alpha-glucosidase, wherein the alpha-glucosidase is related to type 2 diabetes, and the inhibition of the alpha-glucosidase is one of methods for controlling postprandial hyperglycemia, which suggests that the Lactobacillus paracasei KS3 is expected to be applied to the fields of reducing blood sugar, inhibiting obesity and the like.
In a sixth aspect, the invention provides the use of a strain of Lactobacillus paracasei (Lactobacilli sp. Asaei) KS3 according to the first aspect for the preparation of an acetylcholinesterase inhibitor.
The research shows that the probiotic Lactobacillus paracasei KS3 strain can effectively inhibit the activity of acetylcholinesterase, which suggests that the Lactobacillus paracasei KS3 is expected to be used in the fields of enhancing cognitive ability and memory, dilating blood vessels, exciting skeletal muscles and smooth muscles, and the like.
In a seventh aspect, the invention provides the use of a strain of Lactobacillus paracasei (Lactobacilli sp. Asaei) KS3 according to the first aspect for the production of proteases.
The research shows that the probiotics lactobacillus paracasei KS3 strain can produce protease, which suggests that the lactobacillus paracasei KS3 is hopeful to be used in the fields of promoting the digestion and absorption of protein in food, improving the absorption of small peptide and amino acid, resisting allergy and the like.
According to an eighth aspect of the present invention there is provided the use of a strain of Lactobacillus paracasei (Lactobacilli sp. Asaei) KS3 according to the first aspect for the production of gamma-aminobutyric acid.
The research shows that the probiotic Lactobacillus paracasei KS3 strain can produce gamma-aminobutyric acid (GABA), which suggests that the Lactobacillus paracasei KS3 is expected to be used in the fields of improving sleeping quality of organisms, resisting depression, resisting anxiety, reducing blood pressure, improving lipid metabolism, enhancing memory capacity, improving brain activity and the like.
In a ninth aspect, the present invention provides a microbial agent for use in a probiotic function, said microbial agent comprising a strain of lactobacillus paracasei (lactecabilum space) KS3 according to the first aspect.
Preferably, the Lactobacillus paracasei (Lactobacillus paracasei) KS3 strain is a fermented cell mixture. The culture medium used for fermentation is MRS culture medium.
Preferably, in the field of pharmaceutical application, the microbial agent further comprises a pharmaceutically acceptable carrier and/or excipient.
More preferably, the above excipients refer to diluents, binders, lubricants, disintegrants, co-solvents, stabilizers, etc. and some pharmaceutically acceptable bases which are useful in the pharmaceutical field. The carrier is a functional pharmaceutical adjuvant available in the pharmaceutical field and comprises a surfactant, a suspending agent, an emulsifying agent and a plurality of novel pharmaceutical polymer materials, such as cyclodextrin, chitosan, polylactic acid (PLA), polyglycolic acid-polylactic acid copolymer (PLGA), hyaluronic acid and the like.
Preferably, in the field of medical application, the dosage forms of the microbial inoculum comprise tablets, granules, capsules, dripping pills, sustained release agents, oral liquid preparations and injections.
More preferably, the above-mentioned dosage forms refer to clinically usual dosage forms. Pharmaceutical formulations may be administered orally or parenterally (e.g., intravenously, subcutaneously, intraperitoneally, or topically), and if some drugs are unstable under gastric conditions, they may be formulated as enteric coated tablets.
Compared with the prior art, the invention has the beneficial effects that:
the present invention separates a strain of lactobacillus paracasei (lactobacillus paracasei) KS3 from kimchi samples, the strain of lactobacillus paracasei KS3 having various probiotic effects including having superior protease activity, having superior cellulase activity, producing and secreting 3-hydroxybutyric acid, producing and secreting gamma-aminobutyric acid, producing and secreting hyaluronic acid, inhibiting alpha-glucosidase activity and inhibiting acetylcholinesterase activity. Thus, the lactobacillus paracasei strain KS3 has the effects of promoting digestion and absorption of protein foods and improving protein allergy; promoting absorption of cellulose and improving constipation; can be used for resisting inflammation and improving intestinal flora; can be used for resisting depression and relieving hangover; anti-aging and anti-wrinkle; reducing blood glucose; promoting intestinal absorption and peristalsis. Therefore, the novel separated lactobacillus paracasei strain KS3 has various probiotics effects, can be used in the fields of reducing serum cholesterol, promoting digestion, resisting aging and the like, for example, can be prepared into food and medicines for resisting aging and promoting digestion, and has important application value and economic value.
Drawings
FIG. 1 is a phylogenetic tree of Lactobacillus paracasei KS3 and other homologous strains;
FIG. 2 shows the degradation experiment of Lactobacillus paracasei KS3 on milk plates (left, blank; right, experimental group);
FIG. 3 shows the degradation experiment of the cellulose plate by Lactobacillus paracasei KS3 (left, blank; right, experimental group);
FIG. 4 shows that Lactobacillus paracasei KS3 can produce and secrete 3-hydroxybutyric acid;
FIG. 5 shows that Lactobacillus paracasei KS3 can produce and secrete gamma-aminobutyric acid;
FIG. 6 shows that Lactobacillus paracasei KS3 can produce and secrete hyaluronic acid;
FIG. 7 is a graph showing that the secretion of a fermentation broth of Lactobacillus paracasei KS3 significantly inhibited the activity of α -glucosidase;
FIG. 8 shows that the secretable material of the Lactobacillus paracasei KS3 broth significantly inhibited the activity of acetylcholinesterase.
Detailed Description
The following describes the invention in more detail. The description of these embodiments is provided to assist understanding of the present invention, but is not intended to limit the present invention. In addition, the technical features of the embodiments of the present invention described below may be combined with each other as long as they do not collide with each other.
The experimental methods in the following examples, unless otherwise specified, are conventional, and the experimental materials used in the following examples, unless otherwise specified, are commercially available.
The following examples relate to the following experimental materials:
(1) Strains: the strain of Lactobacillus paracasei (Lactobacilli sp. Asaei) KS3 is isolated from kimchi in Guangdong area of China by the laboratory of research and moisturizing of intestinal microbiome of university college of China, and stored in a glycerol tube at-80deg.C for cold preservation. Typically, it is inoculated onto the surface of an MRS solid medium plate and cultured upside down in a thermostatic anaerobic incubator at 37℃for 24 hours to obtain colonies, or cultured in an MRS liquid medium with shaking in a thermostatic anaerobic incubator at 37℃for 24-48 hours to obtain a fermentation broth.
(2) The kit comprises: 3-hydroxybutyric acid (3-HB) detection kit (Cloud-Clone Corp., cat: CEB022 Ge), gamma-aminobutyric acid (GABA) detection kit (Cloud-Clone Corp., cat: CEA900 Ge), hyaluronic acid (also known as hyaluronic acid, HA) detection kit (Cloud-Clone Corp., cat: CEA182 Ge), alpha-glucosidase inhibitor screening kit (abcam, cat: ab 284520), acetylcholinesterase inhibitor screening kit (abnova, cat: KA 6219).
(3) MRS plate: 10g of beef extract, 10g of peptone, 5g of yeast extract, 2g of triammonium citrate, 5g of sodium acetate, 20g of glucose, 2g of dipotassium hydrogen phosphate, 1mL of Tween 80, 0.58g of magnesium sulfate, 0.25g of manganese sulfate, 15g of agar and ddH 2 Filling O to 1L, adjusting pH to 6.2-6.6, and autoclaving at 121deg.C for 20min to obtain MRS plate.
(4) MRS liquid medium: 10g of beef extract, 10g of peptone, 5g of yeast extract, 2g of triammonium citrate, 5g of sodium acetate, 20g of glucose, 2g of dipotassium hydrogen phosphate, 1mL of Tween 80, 0.58g of magnesium sulfate, 0.25g of manganese sulfate and ddH 2 The O is filled to 1L, the pH is regulated to 6.2-6.6, and the mixture is sterilized at 121 ℃ in an autoclave.
(5) MP plate: 10g of skimmed milk powder, 1g of sodium chloride, 10g of beef extract, 10g of peptone, 5g of yeast extract, 20g of glucose, 2g of tri-ammonium citrate, 5g of sodium acetate, 2g of dipotassium hydrogen phosphate, 0.5mL of Tween 80, 0.58g of magnesium sulfate, 0.25g of manganese sulfate, 15g of agar and ddH 2 Filling O to 1L, adjusting pH to 6.2-6.6, autoclaving at 121deg.C for 20min, and making into MP plate.
(6) CMC plate: 10g of sodium carboxymethyl cellulose, 1.5g of ammonium sulfate, 0.3g of manganese sulfate, 0.2g of calcium chloride, 5g of sodium chloride, 0.3g of urea, 10g of beef extract, 10g of peptone, 5g of yeast extract, 20g of glucose, 2g of tri-ammonium citrate, 5g of sodium acetate, 2g of dipotassium hydrogen phosphate, 0.5mL of tween 80, 0.58g of magnesium sulfate, 0.25g of manganese sulfate, 15g of agar and ddH 2 Filling O to 1L, adjusting pH to 6.2-6.6, autoclaving at 121deg.C for 20min, and preparing into CMC plate.
Example 1 isolation and characterization of Lactobacillus paracasei (Lactobacilli sp. Asaei) KS3
The strain of cheese bacillus paracasei Lacticaseibacillusparacasei KS is isolated from a kimchi sample in Guangdong province of China, and is specifically as follows:
repeatedly cleaning pickled cabbage samples for one month purchased from the new phoenix comprehensive meat and vegetable market in Guangzhou sea pearl area with sterile water for 3 times, placing the pickled cabbage samples in a mortar, adding sterile water (v/m=1:10), thoroughly grinding the pickled cabbage samples into homogenate, sucking a proper amount of grinding fluid by a pipette, coating the grinding fluid on an MRS flat plate, and culturing the pickled cabbage pickle samples at room temperature for 3 days. The colonies to be streaked and purified in the separation experiment plates were numbered with a marker and strain numbers were marked on the plates accordingly. Colonies were picked and inoculated onto MRS plates and the strains were purified by plate streaking. If the strain cannot be separated by the method, colonies need to be picked from the enrichment plate, and the colonies are coated on the MRS plate after being subjected to gradient dilution by the MRS liquid culture medium. Reference is made to the "Berger's Manual of identification of bacteria" (eighth edition) and the "manual of identification of fungi" which identify strains belonging to bacteria first, and then the growth of colonies is observed. The primary separation is carried out to obtain a purified strain, the strain is KS3, and after 24 hours of culture, bacterial colony of the strain is round and smooth, the edge is neat, the middle bulge surface is bright, and the bacterial colony is milky and opaque.
Next, after molecular identification by 16S rDNA universal primer (27F: AGAGTTTGATCCTGGCTCAG,1492R: TACGGCTACCTTGTTACGACCTT), the isolated L.Paracasei KS3 strain was subjected to whole genome sequencing by Beijing Baimeike Biotechnology Co. BLAST alignment of the resulting sequence 16S rDNA sequence (SEQ ID No: 1) at NCBI' S Genome database revealed that KS3 strain has >99% homology with known Lactobacillus paracasei 16S rDNA sequences; and analyzed by evolution with homologous strains (FIG. 1), it was confirmed that strain KS3 was Lactobacillus paracasei of the same species and a different strain.
Finally, strain KS3 was deposited with the following information: preservation time: 2022, 09, 27; preservation unit name: china Center for Type Culture Collection (CCTCC); deposit number: cctccc No. M20221510; deposit unit address: chinese university of Wuhan; classification naming: lacticcaseibacillus sparasaei.
The Lactobacillus paracasei is a probiotic strain approved by the country for use in foods, has wide probiotic effects such as antibacterial effect, constipation improvement and blood pressure reduction, etc., but different sources of strains have different effects, which means that the novel Lactobacillus paracasei KS3 isolated from kimchi in Guangdong area of the present invention can be used as a probiotic and may have novel effects and functions.
L.paracasei KS316S rDNA sequence(1450 bp，SEQ ID No：1)：
TGCTATACaTGCAGTCGaACGAGTTCTCGTTGATGATCGGTGCTTGCACCGAGATTCAACATGGAACGAGTGGCGGACGGGTGAGTAACACGTGGGTAACCTGCCCTTAAGTGGGGGATAACATTTGGAAACAGATGCTAATACCGCATAGATCCAAGAACCGCATGGTTCTTGGCTGAAAGATGGCGTAAGCTATCGCTTTTGGATGGACCCGCGGCGTATTAGCTAGTTGGTGAGGTAATGGCTCACCAAGGCGATGATACGTAGCCGAACTGAGAGGTTGATCGGCCACATTGGGACTGAGACACGGCCCAAACTCCTACGGGAGGCAGCAGTAGGGAATCTTCCACAATGGACGCAAGTCTGATGGAGCAACGCCGCGTGAGTGAAGAAGGCTTTCGGGTCGTAAAACTCTGTTGTTGGAGAAGAATGGTCGGCAGAGTAACTGTTGTCGGCGTGACGGTATCCAACCAGAAAGCCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTATCCGGATTTATTGGGCGTAAAGCGAGCGCAGGCGGTTTTTTAAGTCTGATGTGAAAGCCCTCGGCTTAACCGAGGAAGCGCATCGGAAACTGGGAAACTTGAGTGCAGAAGAGGACAGTGGAACTCCATGTGTAGCGGTGAAATGCGTAGATATATGGAAGAACACCAGTGGCGAAGGCGGCTGTCTGGTCTGTAACTGACGCTGAGGCTCGAAAGCATGGGTAGCGAACAGGATTAGATACCCTGGTAGTCCATGCCGTAAACGATGAATGCTAGGTGTTGGAGGGTTTCCGCCCTTCAGTGCCGCAGCTAACGCATTAAGCATTCCGCCTGGGGAGTACGACCGCAAGGTTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTACCAGGTCTTGACATCTTTTGATCACCTGAGAGATCAGGTTTCCCCTTCGGGGGCAAAATGACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTATGACTAGTTGCCAGCATTTAGTTGGGCACTCTAGTAAGACTGCCGGTGACAAACCGGAGGAAGGTGGGGATGACGTCAAATCATCATGCCCCTTATGACCTGGGCTACACACGTGCTACAATGGATGGTACAACGAGTTGCGAGACCGCGAGGTCAAGCTAATCTCTTAAAGCCATTCTCAGTTCGGACTGTAGGCTGCAACTCGCCTACACGAAGTCGGAATCGCTAGTAATCGCGGATCAGCACGCCGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACACCATGAGAGTTTGTAACACCCGAAGCCGGTGGCGTAACCCTTtTAGGGAGCGAGCCGTCTAA。
Experimental example 1 function of Lactobacillus paracasei (Lactobacilli sp. Asaei) KS3 and use thereof
(1) Lactobacillus paracasei KS3 strain can produce protease for degrading milk protein
The identification and measurement of the ability of Lactobacillus paracasei KS3 to secrete proteolytic proteins was performed according to the agar well diffusion assay using a skim milk plate medium (MP plate). In the test, 3uL of Lactobacillus paracasei KS3 strain solution with a concentration of 10Abs was added dropwise to the test group, and 3uL of blank MRS medium was added dropwise to the control group. The cells were cultured in an anaerobic incubator at 37℃for 3 days in an inverted manner. The results showed that KS3 significantly degraded protein and formed a distinct degradation circle (fig. 2) compared to the control with the blank medium added dropwise, indicating that lactobacillus paracasei KS3 produced protease. It can be seen that the use of Lactobacillus paracasei KS3 as a probiotic strain promotes the digestion and absorption of proteins in food by the human body, and improves the absorption of small peptides and amino acids. And can be used for resisting allergy (improving food allergy caused by protein dyspepsia or non-absorption). In addition, the method can also be used for extracting protease and is applied to the production in the protease fields of food industry, washing industry and the like; can also be used in microbial feed to help animals digest and absorb nutrition, and improve the utilization rate of the feed.
(2) The strain of cheese bacillus KS3 can produce cellulase
The identification and measurement of the cellulose degrading ability of Lactobacillus paracasei KS3 were carried out according to the agar well diffusion method with slight modification, and the cellulose plate medium used was MP medium. In the test, 3uL of Lactobacillus paracasei KS3 strain solution at 10Abs was added dropwise to the test group, while 3uL of blank MRS medium was added dropwise to the control group. Congo red staining was performed after 3 days of inversion culture in an anaerobic incubator at 37 ℃. The results showed that KS3 significantly degraded cellulose compared to the control with the blank medium drop-in, forming a distinct degradation circle (fig. 3), indicating that lactobacillus paracasei KS3 produced cellulase.
It can be seen that the probiotic Lactobacillus paracasei KS3 strain can serve several purposes by producing cellulase enzymes: (1) to facilitate the digestive absorption of dietary components; (2) improving constipation: the decomposition of cellulose in the intestinal tract produces a certain water content with the effect of softening the stool; (3) Cholesterol reduction is the most important effect of cellulose, because the soluble fiber can inhibit the absorption of cholesterol by human body after being absorbed by human body, can be combined with cholesterol in intestinal tract, quickens the metabolism of cholesterol in human body, prevents human body from inducing hyperlipidemia due to hypercholesteremia, and can also reduce the incidence rate of arteriosclerosis and coronary heart disease; (4) The non-sweet 'sugar' of cellulose can slow down the absorption of glucose by blood, balance the concentration of blood sugar and promote the sensitivity of muscle and fat cells to insulin, thereby preventing and assisting in treating diabetes.
In addition, the cheese bacillus paracasei KS3 can also be used for fermenting and extracting cellulase, and has wide application in the food industry and the environmental industry; can be applied to degrading cell walls of pathogenic fungi and controlling diseases; can be applied to the decomposition of cellulose in compost; can also be used for preparing livestock and poultry raising feed, such as monogastric animal feed for pigs, chickens and the like, so as to overcome the defect that cellulose cannot be utilized.
(3) The Lactobacillus paracasei KS3 strain can produce and secrete 3-hydroxybutyric acid (3-HB)
Lactobacillus paracasei KS3 cultured in MRS broth to stationary phase was expanded at 1:30 to new MRS broth, bacterial suspension was harvested at 24h of stationary phase, supernatant of the broth was harvested by centrifugation at 10,000Xg at 4℃for 10min, and 3-HB concentration of supernatant of the broth was determined by 3-HB specific ELISA kit (CEB 022 Ge). The results showed that the concentration of 3-HB in the supernatant of KS3 was 1.76. Mu.g/mL compared to the absence of 3-HB in the blank medium MRS, indicating that Lactobacillus paracasei KS3 can produce and secrete 3-hydroxybutyric acid during the stationary phase (FIG. 4).
3-HB provides energy for various physical activities and is a potential energy/functional food that has been added to athlete drinks, so the probiotic Lactobacillus paracasei KS3 can be used for the addition of energy foods. In addition, in view of the fact that 3-HB can effectively resist osteoporosis, prevent and treat chronic syndromes (hypertension, alcoholic fatty liver, enteritis and intestinal cancer), improve brain cognitive functions (improving learning and memory capacity, protecting glial cells, improving Alzheimer's disease) and improve lipid metabolism. Thus, the probiotic Lactobacillus paracasei KS3 strain may serve several purposes as above by producing 3-hydroxybutyric acid.
Meanwhile, 3-hydroxybutyric acid is an endogenous small molecular substance naturally produced by an organism, has an important function of maintaining the integrity of colorectal tissues, and has the functions of maintaining intestinal health, preventing colon diseases and diminishing inflammation and productivity. 3-HB treatment promotes the proliferation of beneficial intestinal bacteria, alleviates the symptoms of multiple sclerosis mice, and has great potential in regulating flora and improving health. Thus the probiotic Lactobacillus paracasei KS3 strain also helps to improve intestinal flora and alleviate intestinal inflammation.
(4) The Lactobacillus paracasei KS3 strain produces and secretes gamma-aminobutyric acid (GABA)
The Lactobacillus paracasei KS3 cultured in MRS liquid medium to stationary phase was expanded into new MRS liquid medium at a dilution ratio of 1:30, bacterial suspension was collected at 24 hours of culture to stationary phase, supernatant of the fermentation broth was collected after centrifugation at 10,000Xg and 4℃for 10min, and GABA concentration of the fermentation broth supernatant was measured by GABA specific ELISA kit (CEA 900 Ge). The results showed that the concentration of GABA in the fermentation supernatant of KS3 was significantly increased compared to the low concentration of GABA in the blank medium MRS, and the accumulated amount was 95.13pg/mL, indicating that lactobacillus paracasei KS3 can produce and secrete γ -aminobutyric acid in the stationary phase (fig. 5).
Gamma-aminobutyric acid is an important central nervous system inhibitory neurotransmitter, and is widely present in animals, plants and microorganisms. It has been demonstrated that GABA, a small molecular weight non-protein amino acid, is food safe and can be used as a food additive. Research shows that intake of a certain amount of GABA has the physiological effects of improving sleeping quality of organisms, resisting depression, resisting anxiety, reducing blood pressure, improving lipid metabolism, enhancing memory and brain activity, accelerating brain metabolism, strengthening liver and kidney, promoting ethanol metabolism (dispelling alcohol effect), improving climacteric syndrome and the like.
Thus, the probiotic Lactobacillus paracasei KS3 strain can exert the above multiple uses by the effect of producing gamma-aminobutyric acid.
(5) The Lactobacillus paracasei KS3 strain produces and secretes Hyaluronic Acid (HA)
The Lactobacillus paracasei KS3 cultured in MRS liquid medium to stationary phase was spread to new MRS liquid medium at a dilution ratio of 1:30, bacterial suspension was collected at 24h of stationary phase, and after centrifugation at 10,000Xg and 4℃for 10min, the supernatant of the fermentation broth was collected, and the HA concentration of the supernatant of the fermentation broth was measured by means of a hyaluronic acid (also called hyaluronic acid, HA) specific ELISA kit (CEA 182 Ge). The results showed that the concentration of HA in the fermentation supernatant of KS3 was significantly increased compared to the low concentration of HA in the blank medium MRS, with an accumulated amount of 208.3ng/mL, indicating that lactobacillus paracasei KS3 can produce and secrete hyaluronic acid during stationary phase (fig. 6).
Hyaluronic acid, also known as hyaluronic acid, is a biodegradable, biocompatible, non-toxic, non-allergenic polymer with a variety of biological functions. Has anti-inflammatory and anti-angiogenesis effects, and has strong anti-aging, moisturizing and wrinkle smoothing abilities. The anti-wrinkle agent is beneficial to skin anti-wrinkle, promotes wound anti-inflammation and healing, can be used as an anti-wrinkle agent, and has the potential of developing skin cosmetics. In addition, HA HAs high lubricating, water absorbing and retaining ability, and can affect various cell functions such as migration, adhesion and proliferation, so that HA is also widely used in biomedical fields such as ophthalmic surgery, arthritis treatment, wound healing scaffolds, tissue engineering, implant materials, and the like.
Thus, the probiotic Lactobacillus paracasei KS3 strain can exert the above multiple uses by virtue of hyaluronic acid production.
(6) The fermentation liquor of the Lactobacillus paracasei KS3 strain can effectively inhibit the activity of alpha-glucosidase
The Lactobacillus paracasei KS3 cultured in the MRS liquid medium to the stationary phase was spread in a new MRS liquid medium at a dilution ratio of 1:30, a bacterial suspension was collected at 24 hours of the stationary phase, and after centrifugation at 10,000Xg for 10 minutes at 4℃a supernatant of the fermentation broth was collected, and the effect of the supernatant of the fermentation broth on the enzyme activity ability of the α -glucosidase to hydrolyze glucose was measured by an α -glucosidase inhibitor screening kit (ab 284520). The results showed that the fermentation supernatant of KS3 significantly inhibited the ability of α -glucosidase to hydrolyze glucose compared to the non-inhibitory effect of the blank medium MRS, with an inhibition rate of about 72.16%, indicating that the fermentation broth of lactobacillus paracasei KS3 can effectively inhibit the activity of α -glucosidase (fig. 7).
Alpha-glucosidase, an enzyme that plays a role in carbohydrate breakdown, is associated with type 2 diabetes, and inhibition of alpha-glucosidase is one of the methods of controlling postprandial hyperglycemia, thereby contributing to the treatment of diabetes. Thus, α -glucosidase inhibitors help to maintain blood glucose levels and can improve diabetic complications. Furthermore, inhibition of α -glucosidase activity may control obesity.
Thus, the probiotic Lactobacillus paracasei KS3 strain has an inhibitory activity on α -glucosidase, which makes it a potential hypoglycemic and obesity inhibiting probiotic.
(7) The fermentation liquid of the Lactobacillus paracasei KS3 strain can effectively inhibit the activity of acetylcholinesterase
The Lactobacillus paracasei KS3 cultured in the MRS liquid medium to the stationary phase was expanded into a new MRS liquid medium at a dilution ratio of 1:30, a bacterial suspension was collected at 24 hours of the stationary phase, and after centrifugation at 10,000Xg for 10 minutes at 4 ℃, a fermentation broth supernatant was collected, and the inhibitory activity of the fermentation broth supernatant on acetylcholinesterase (AchE) was measured by an acetylcholinesterase inhibitor screening kit (KA 6219). The results showed that the fermentation supernatant of KS3 significantly inhibited the activity of acetylcholinesterase compared to the non-inhibitory effect of the blank medium MRS, with an inhibition rate of about 22.67%, indicating that the fermentation broth of Lactobacillus paracasei KS3 can effectively inhibit the activity of acetylcholinesterase (FIG. 8).
Acetylcholinesterase inhibitors allow cholinergic to accumulate at the synapse under the action of acetylcholine released from the nerve fiber tip through reversible inhibition of acetylcholinesterase, excite cholinergic receptors, prolong and augment the action of acetylcholine. Acetylcholinesterase inhibitors can enhance cognitive ability and memory (improve Alzheimer's disease, improve cognitive dysfunction), dilate blood vessels (improve heart rate overspeed), excite skeletal and smooth muscles (improve constipation, postoperative abdominal distension, postoperative urinary retention).
Thus, the probiotic Lactobacillus paracasei KS3 strain inhibits acetylcholinesterase activity, excites skeletal and smooth muscles of the intestinal tract, which makes it a potential probiotic for promoting gastrointestinal absorption and peristalsis.
Taken together, the novel isolated strain KS3 of lactobacillus paracasei of the present invention has a variety of probiotic efficacy: (1) has excellent protease activity; (2) has excellent cellulase activity; (3) 3-hydroxybutyric acid may be produced and secreted; (4) gamma-aminobutyric acid can be produced and secreted; (5) can produce and secrete hyaluronic acid; (6) can inhibit alpha-glucosidase activity; (7) can inhibit acetylcholinesterase activity. It can be seen that the Lactobacillus paracasei strain KS3 has important application value and economic value.
The embodiments of the present invention have been described in detail above, but the present invention is not limited to the described embodiments. It will be apparent to those skilled in the art that various changes, modifications, substitutions and alterations can be made to these embodiments without departing from the principles and spirit of the invention, and yet fall within the scope of the invention.
Claims (10)
1. A strain of lactobacillus paracasei (lacticemia straposasaei) KS3, wherein said strain of lactobacillus paracasei KS3 was deposited with the chinese collection of typical cultures at month 27 of 2022 under the accession number: cctcrno: M20221510; the 16SrDNA complete sequence of the Lactobacillus paracasei KS3 strain is shown in SEQ ID No: 1.
2. Use of a strain of lactobacillus paracasei (lacteceibacillus sp. Asaei) KS3 according to claim 1 for the production of cellulases.
3. Use of a strain of lactobacillus paracasei (lacteceibacillus sp. Asaei) KS3 according to claim 1 for the production of 3-hydroxybutyric acid.
4. Use of a strain of lactobacillus paracasei (lacteceibacillus sp. Asaei) KS3 according to claim 1 for the production of hyaluronic acid.
5. Use of a strain of lactobacillus paracasei (lacticemia spacebasei) KS3 according to claim 1 for the preparation of an alpha-glucosidase inhibitor.
6. Use of a strain of lactobacillus paracasei (lacticemia spacebasei) KS3 according to claim 1 for the preparation of an acetylcholinesterase inhibitor.
7. Use of a strain of lactobacillus paracasei (lacteceibacillus sp. Asaei) KS3 according to claim 1 for the production of proteases.
8. Use of a strain of lactobacillus paracasei (lacticeibacillus sparasaei) KS3 according to claim 1 for the production of gamma-aminobutyric acid.
9. A microbial agent for use in a probiotic function, comprising the lactobacillus paracasei (lacticeillulasporaseii) KS3 strain of claim 1.
10. A bacterial agent for use in a probiotic composition according to claim 9, wherein said lactobacillus paracasei (lacticemia sp. Asasei) KS3 strain is a fermented cell mixture.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310235096.9A CN116286519B (en) | 2023-03-13 | 2023-03-13 | Lactobacillus paracasei KS3 and application thereof in preparation of anti-aging and digestion-aiding foods and medicines |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310235096.9A CN116286519B (en) | 2023-03-13 | 2023-03-13 | Lactobacillus paracasei KS3 and application thereof in preparation of anti-aging and digestion-aiding foods and medicines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116286519A CN116286519A (en) | 2023-06-23 |
| CN116286519B true CN116286519B (en) | 2023-11-28 |
Family
ID=86820198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310235096.9A Active CN116286519B (en) | 2023-03-13 | 2023-03-13 | Lactobacillus paracasei KS3 and application thereof in preparation of anti-aging and digestion-aiding foods and medicines |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116286519B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210063994A (en) * | 2019-11-25 | 2021-06-02 | 국립낙동강생물자원관 | Feed additives for animal containing Lactobacillus paracasei NSMJ15 |
| CN114717157A (en) * | 2022-05-07 | 2022-07-08 | 山东百沃生物科技有限公司 | Lactobacillus paracasei for preventing streptococcus infection of infants and application thereof |
| CN115261264A (en) * | 2022-07-07 | 2022-11-01 | 内蒙古农业大学 | Lactobacillus paracasei PC804 and application thereof |
| CN115340965A (en) * | 2022-07-07 | 2022-11-15 | 内蒙古农业大学 | Lactobacillus paracasei PC724 and application thereof |
| WO2022236935A1 (en) * | 2021-05-14 | 2022-11-17 | 艾兰得生物科技研究泰州有限公司 | Probiotic having effect of inhibiting growth of proteus mirabilis, and fermentation broth and use thereof |
| CN115725469A (en) * | 2022-11-28 | 2023-03-03 | 广西大学 | Lactobacillus paracasei and application thereof |
-
2023
- 2023-03-13 CN CN202310235096.9A patent/CN116286519B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210063994A (en) * | 2019-11-25 | 2021-06-02 | 국립낙동강생물자원관 | Feed additives for animal containing Lactobacillus paracasei NSMJ15 |
| WO2022236935A1 (en) * | 2021-05-14 | 2022-11-17 | 艾兰得生物科技研究泰州有限公司 | Probiotic having effect of inhibiting growth of proteus mirabilis, and fermentation broth and use thereof |
| CN114717157A (en) * | 2022-05-07 | 2022-07-08 | 山东百沃生物科技有限公司 | Lactobacillus paracasei for preventing streptococcus infection of infants and application thereof |
| CN115261264A (en) * | 2022-07-07 | 2022-11-01 | 内蒙古农业大学 | Lactobacillus paracasei PC804 and application thereof |
| CN115340965A (en) * | 2022-07-07 | 2022-11-15 | 内蒙古农业大学 | Lactobacillus paracasei PC724 and application thereof |
| CN115725469A (en) * | 2022-11-28 | 2023-03-03 | 广西大学 | Lactobacillus paracasei and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116286519A (en) | 2023-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102146429B1 (en) | Strain of bifidobacterium animalis ssp. animalis | |
| CN116555076B (en) | Bifidobacterium longum subspecies longum MY1 and application thereof in preparation of food and medicine for relaxing bowels and protecting intestines | |
| CN116555075B (en) | Lactobacillus plantarum JF1 and application thereof in preparation of anti-aging food and drug | |
| CN113337440B (en) | Lactobacillus salivarius MG-587 and application thereof | |
| CN116555074B (en) | Lactobacillus brevis JT1 and application thereof in preparation of hypoglycemic drugs | |
| CN117004503B (en) | Saliva combined lactobacillus MB1 and application thereof in preparation of food and medicine for assisting sleep and regulating intestines and stomach | |
| CN116286519B (en) | Lactobacillus paracasei KS3 and application thereof in preparation of anti-aging and digestion-aiding foods and medicines | |
| CN116656526B (en) | Lactobacillus plantarum JF4 and application thereof in preparation of blood sugar and cholesterol reducing foods and medicines | |
| CN116218733B (en) | Lactobacillus rhamnosus XY5 and application thereof in preparing antiallergic and digestion-promoting food and drug | |
| CN114410532A (en) | Bifidobacterium longum for reducing plasma trimethylamine oxide and caecum trimethylamine levels and application thereof | |
| CN116814464B (en) | Fermented lactobacillus mucilaginosus JF5 and application thereof in preparation of lipid-reducing and digestion-aiding foods and medicines | |
| CN117286045B (en) | Bifidobacterium longum subspecies longum KS2 and application thereof in preparation of anti-aging medicines | |
| CN116574634B (en) | Streptococcus salivarius thermophilus subspecies JF2 and application thereof in preparation of anti-inflammatory and lipid-relieving food and drug | |
| CN117343875A (en) | Lactobacillus gasseri MY5 and application thereof in preparation of anti-inflammatory, laxative and intestine-protecting food and medicine | |
| CN117363524B (en) | Lactobacillus gasseri MY4 and application thereof in preparation of sleep-aiding and whitening medicines | |
| CN117402768B (en) | Lactobacillus reuteri KA1 and application thereof in preparation of anti-inflammatory and anti-tumor medicines | |
| KR102495246B1 (en) | Lactobacillus helveticus BCC-LH-04 having body fat-reducing activity and compositions comprising the same | |
| CN117431179A (en) | Lactobacillus gasseri MY4 and application thereof in preparing food and medicine for regulating intestines and stomach and reducing uric acid | |
| CN117946936A (en) | Lactobacillus plantarum XY4 and application thereof in preparation of digestion-aiding and anti-inflammatory food and drug | |
| CN117946942A (en) | Lactobacillus plantarum MY3 and application thereof in preparing food and medicine for regulating intestines and stomach and improving constipation | |
| CN117384790A (en) | Pediococcus pentosaceus KS5 and application thereof in preparation of anti-inflammatory and sleep-aiding foods and medicines | |
| CN117946937A (en) | Lactobacillus plantarum XY1 and application thereof in preparation of foods and medicines for reducing blood sugar and improving gout | |
| CN117866841A (en) | Enterococcus faecalis XY2 and application thereof in preparing food and medicine for coordinating intestines and stomach and improving gout | |
| CN117946939A (en) | Lactobacillus plantarum SM2 and application thereof in preparation of cholesterol-lowering and sleep-aiding foods and medicines | |
| CN117946940A (en) | Lactobacillus plantarum SM1 and application thereof in preparing food and medicine for regulating intestines and stomach and losing weight |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |